Abstract:The recognition of peptides bound to class I major histocompatibility complex (MHC-I) receptors by T-cell receptors (TCRs) is a determinant of triggering the adaptive immune response. While the exact molecular features that drive the TCR recognition are still unknown, studies have suggested that the geometry of the joint peptide-MHC (pMHC) structure plays an important role. As such, there is a definite need for methods and tools that accurately predict the structure of the peptide bound to the MHC-I receptor. In the past few years, many pMHC structural modeling tools have emerged that provide high-quality modeled structures in the general case. However, there are numerous instances of non-canonical cases in the immunopeptidome that the majority of pMHC modeling tools do not attend to, most notably, peptides that exhibit non-standard amino acids and post-translational modifications (PTMs) or peptides that assume non-canonical geometries in the MHC binding cleft. Such chemical and structural properties have been shown to be present in neoantigens; therefore, accurate structural modeling of these instances can be vital for cancer immunotherapy. To this end, we have developed APE-Gen2.0, a tool that improves upon its predecessor and other pMHC modeling tools, both in terms of modeling accuracy and the available modeling range of non-canonical peptide cases. Some of the improvements include (i) the ability to model peptides that have different types of PTMs such as phosphorylation, nitration, and citrullination; (ii) a new and improved anchor identification routine in order to identify and model peptides that exhibit a non-canonical anchor conformation; and (iii) a web server that provides a platform for easy and accessible pMHC modeling. We further show that structures predicted by APE-Gen2.0 can be used to assess the effects that PTMs have in binding affinity in a more accurate manner than just using solely the sequence of the peptide. APE-Gen2.0 is freely available at https://apegen.kavrakilab.org.

A Chemical Approach to Assess the Impact of Post-translational Modification on MHC Peptide Binding and Effector Cell Engagement

Mechano-regulation of Peptide-MHC Class I Conformations Determines TCR Antigen Recognition.

Antigen presentation of post‐translationally modified peptides in major histocompatibility complexes

Chaperone-mediated MHC-I peptide exchange in antigen presentation

Quantitative analysis of MHC class II peptide exchange reveals pivotal role of peptide association rate

Modulation of T Cell Responses with MHC-derived Peptides.

Major Histocompatibility Complex (MHC) Class I and MHC Class II Proteins: Conformational Plasticity in Antigen Presentation

Introduction of Non-natural Amino Acids Into T-Cell Epitopes to Mitigate Peptide-Specific T-Cell Responses

Quantifying conformational changes in the TCR:pMHC-I binding interface

The Three-Dimensional Structure of Peptide-MHC Complexes

An Efficient Approach to the Accurate Prediction of Mutational Effects in Antigen Binding to the MHC1

Structurally silent peptide anchor modifications allosterically modulate T cell recognition in a receptor-dependent manner

APE-Gen2.0: Expanding Rapid Class I Peptide–Major Histocompatibility Complex Modeling to Post-Translational Modifications and Noncanonical Peptide Geometries

A platform for mapping reactive cysteines within the immunopeptidome

Molecular Dynamics Simulations Reveal Canonical Conformations in Different pMHC/TCR Interactions

Development of a Stable Peptide-Major Histocompatibility Complex (MHC) via Sortase and Click Chemistry

TCR Recognition of Peptide–MHC-I: Rule Makers and Breakers

Machine learning application to predict binding affinity between peptide containing non-canonical amino acids and HLA0201

Validation of novel conditional ligands and large-scale detection of antigen-specific T cells for H-2Dd and H-2Kd

CryoEM structure of an MHC-I/TAPBPR peptide bound intermediate reveals the mechanism of antigen proofreading

Uncovering the modified immunopeptidome reveals insights into principles of PTM-driven antigenicity